Principal Kulika reflects on the in-person conference, her panels, and more.
Principal Kulika’s reflections on BioFuture and whether the value-based care model is investible.
Higher drug approval rates, lower clinical trial costs, and improved efficacy are within reach with the right tools.
Currently, the only treatment for hydrocephalus is to place a shunt in order to drain the excess fluid. Patients rely on these shunts for the rest of their lives but shunts are bound to fail. The failure rate is as high as 50% just 18 months after the placement.
Our team at Creative Ventures invests in technologies that address the inexorable rise in healthcare costs globally. These costs are driven by the secular demographic trend of aging populations and rising chronic disease—and without innovations within healthcare, will force us to face a grim tradeoff of either consuming all of our economic output in maintainingContinue reading “Healthcare Round-Up”
Healthcare has been slow to embrace technology, but now digital transformation in health care is accelerating. The increased demand on the healthcare system triggered many healthcare organizations to make changes to their delivery systems. Hospitals and clinics used telemedicine and remote patient monitoring services to provide meaningful solutions and supplement some healthcare delivery and services deficiencies.
The sheer scale of the healthcare system is mesmerizing. In the US alone, $11,072 per capita spending (in 2019) and at around 320 million in population means that we’re looking at $3 trillion in annual spending.
And even though the US is the largest spender, spending per capita has been rising across the entire world, driving healthcare to make up a larger and larger share of total global GDP.
But, as experienced founders know, the sheer size of a market alone doesn’t matter that much. What matters is how attainable it is for your specific business and business model.
For founders in the healthcare sector, this means avoiding the number one faux pax; forgetting the “business” part of the healthcare system.
There is currently a lot of debate around the efficacy and value of the American healthcare system, but we believe a large portion of its problems are due to the fact that it is better equipped to treat acute conditions rather than chronic conditions. In addition, we often don’t have good drugs or other incentivesContinue reading “It’s a Good Time to Invest in Healthcare Diagnostics. Here’s Why.”
The underlying macrotrends, current solutions and investment opportunities Creative Ventures recently led an investment into VenoStent, an advanced-material technology company working on eliminating the 50%+ failure rate in vascular-access surgery required to initiate hemodialysis. Here we unravel the underlying macrotrends driving the development of solutions and investment opportunities in this sector. The kidneys are amongContinue reading “Kidney Disease: A Silent (and Costly) Killer”